Expression and ligand binding of alpha 2 beta 1 integrin on breast carcinoma cells.
We examined the expression and ligand specificity of the alpha 2 beta 1 integrin on human mammary epithelial cells (HMEC) and a panel of breast carcinoma cell lines in vitro. We found that the alpha 2 beta 1 integrin was universally, but quite variably expressed on these cells by FACS analysis. No significant correlation was observed between its expression and other known cellular phenotypes. Substrate attachment assays using blocking antibodies demonstrated that alpha 2 beta 1 integrin served as a receptor for collagen on HMEC and almost all breast carcinoma cells. However, its contribution to laminin binding of these cells appeared to be related to cellular differentiation as evaluated by sex steroid receptor status and by markers of epithelial-mesenchymal transition, i.e. loss of E-cadherin and expression of vimentin. Two different populations of non-malignant immortalized HMEC (184A1N4 and MCF-10A) contained cells capable of using alpha 2 beta 1 integrin as a laminin receptor. Breast cancer cell lines positive for estrogen receptor (ER) and E-cadherin (MCF-7, T47D, ZR75-1) could also use alpha 2 beta 1 integrin as a laminin receptor. Conversely, alpha 2 beta 1 integrin appeared to be incapable of binding to laminin or to be a very minor receptor for laminin on metastatic ER-negative breast carcinoma cells that expressed vimentin (MDA-MB 231, MDA-MB 435, and MDA-MB 436). These findings suggest that the ligand specificity of alpha 2 beta 1 integrin, i.e. its function as a laminin receptor, may be regulated during the malignant progression of breast carcinoma cells. A reduced contribution of alpha 2 beta 1 integrin to the cellular laminin binding appears to be associated with an increased malignant phenotype and with an epithelial-mesenchymal transition of breast carcinoma cells.
Maemura
M
M
Lombardi Cancer Research Center, Georgetown University, Washington, DC 20007, USA.
Akiyama
S K
SK
Woods
V L
VL
Dickson
R B
RB
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001667:Binding, Competitive; D001940:Breast / Q000166:cytology / Q000378:metabolism / Q000648:ultrastructure; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D002448:Cell Adhesion / Q000502:physiology; D003094:Collagen / Q000378:metabolism; D004847:Epithelial Cells; D004848:Epithelium / Q000378:metabolism; D006801:Humans; D016023:Integrins / Q000378:metabolism* / Q000502:physiology; D007797:Laminin / Q000378:metabolism; D008024:Ligands; D010641:Phenotype; D038981:Receptors, Collagen; D011960:Receptors, Estrogen / Q000502:physiology; D011980:Receptors, Progesterone / Q000502:physiology; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D016023:Integrins; D007797:Laminin; D008024:Ligands; D038981:Receptors, Collagen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D003094:Collagen